← Leaderboards
Michael J. Detke
Embera Neurotherapeutics, Inc.
$20,412,122
Attributed
$20,412,122
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $12.6M · FY2016–25$20M$15M$10M$5M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,412,122 · 2
By mechanism
R01$12,591,952 · 1
U01$7,820,170 · 1
Top collaborators
No co-investigators on record.
Most similar at Embera Neurotherapeutics, Inc.
Same institution · by research overlap
- Bruce McCarthy$3,380,100
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposPhase 3 StudyPhase 1 StudySafetyAnimalsDoseRandomizedPlacebosDrug KineticsAdverse EffectsAnimal ModelAmyloid Beta-Protein PrecursorAdmission ActivityAntibodiesAccident And Emergency DepartmentAmyloid Beta-42AutopsyAmyloidAddictionBacteriaBaseBenzodiazepinesBenzoylecgonineAuthorization Documentation
Grant awards (3)
A Randomized, Double-Blind, Placebo-Controlled Study of LHP588 in Subjects with P. gingivalis-Positive Alzheimer's Disease$12,591,952
R01 · FY2025 · AG · contact PI
EMB-001: A novel combination therapy for the treatment of cocaine-use disorder$3,762,556
U01 · FY2018 · DA · contact PI
EMB-001: A novel combination therapy for the treatment of cocaine-use disorder$4,057,614
U01 · FY2016 · DA · contact PI